Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Authors:
- Abdulazeez SalawuASAbdulazeez Salawu
- Ben X. WangBWBen X. Wang
- Ming HanMHMing Han
- Caryn GeadyCGCaryn Geady
- Alya HeiraliAHAlya Heirali
- Hal K. BermanHBHal K. Berman
- Thomas D. PfisterTPThomas D. Pfister
- Alberto Hernando-CalvoAHAlberto Hernando-Calvo
- Esmail Mutahar Al-EzziEAEsmail Mutahar Al-Ezzi
- Lee-Anne StaynerLSLee-Anne Stayner
- Abha A. GuptaAGAbha A. Gupta
- Olubukola AyodeleOAOlubukola Ayodele
Open Access
- 25 November 2025
- other
- Published by American Association for Cancer Research (AACR)